Principal Investigator
Georgios Pongas
Enrollment Status
Not Accepting
Clinical Trial ID
Institutional Protocol #
20230797
Clinical Trial Summary
An Open-Label, Multicenter Phase 2 Study to Evaluate the Efficacy and Safety of the BCL2 Inhibitor Sonrotoclax (BGB-11417) as Monotherapy and in Combination with Zanubrutinib (BGB-3111) in Patients With Waldenstrm Macroglobulinemia
Phase
Phase II
Funding Agency/Sponsor
Industrial
Disease
Lymphoma
Contact Information
Phone Number
305-243-2647